ATE391779T1 - Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal - Google Patents

Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal

Info

Publication number
ATE391779T1
ATE391779T1 AT98960004T AT98960004T ATE391779T1 AT E391779 T1 ATE391779 T1 AT E391779T1 AT 98960004 T AT98960004 T AT 98960004T AT 98960004 T AT98960004 T AT 98960004T AT E391779 T1 ATE391779 T1 AT E391779T1
Authority
AT
Austria
Prior art keywords
potassium channel
human brain
biomolecule
novel
kcnq2 potassium
Prior art date
Application number
AT98960004T
Other languages
English (en)
Inventor
Jayashree Aiyar
Claudia Ann Iannotti
Edward Philip Christian
Naomi Jean Logsdon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE391779T1 publication Critical patent/ATE391779T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT98960004T 1997-12-13 1998-12-11 Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal ATE391779T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726339.6A GB9726339D0 (en) 1997-12-13 1997-12-13 Human-derived tissue-specific potassium channel

Publications (1)

Publication Number Publication Date
ATE391779T1 true ATE391779T1 (de) 2008-04-15

Family

ID=10823549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960004T ATE391779T1 (de) 1997-12-13 1998-12-11 Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal

Country Status (9)

Country Link
US (1) US20060183105A1 (de)
EP (1) EP1036175B1 (de)
JP (1) JP2002508178A (de)
AT (1) ATE391779T1 (de)
AU (1) AU1569599A (de)
DE (1) DE69839347T2 (de)
ES (1) ES2303359T3 (de)
GB (1) GB9726339D0 (de)
WO (1) WO1999031232A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413719B1 (en) 1997-10-24 2002-07-02 University Of Utah Research Foundation KCNQ2 and KCNQ3-potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies
US6649371B1 (en) 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
JP2003506388A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
WO2001027253A1 (en) * 1999-10-08 2001-04-19 Caliper Technologies Corp. Use of nernstein voltage sensitive dyes in measuring transmembrane voltage
DE10013732A1 (de) * 2000-03-21 2001-09-27 Aventis Pharma Gmbh Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
US6617131B2 (en) 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
US7442519B2 (en) 2002-06-25 2008-10-28 Serono Genetics Institute, S.A. KCNQ2-15 potassium channel
DE60316161T2 (de) * 2002-06-25 2008-06-19 Serono Genetics Institute S.A. Neue kcnq-polypeptide und deren verwendung bei der diagnose von geisteskrankheiten
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
US20140093946A1 (en) * 2012-09-28 2014-04-03 General Electric Company System for optimizing the introduction of nucleic acids into cells using magnetic particles
EP4367217A1 (de) * 2021-07-08 2024-05-15 Baylor College of Medicine Auf rekombinanten mikroorganismen basierende verfahren und zusammensetzungen zur behandlung von krankheiten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330744A (en) * 1995-12-22 1999-02-25 Univ Utah Res Found A long qt syndrome gene which encodes kvlqt1 and its association with mink
JPH09191882A (ja) * 1996-01-16 1997-07-29 Japan Tobacco Inc ヒト新規ｋ＋チャネル蛋白質をコードするｄｎａおよびその断片

Also Published As

Publication number Publication date
ES2303359T3 (es) 2008-08-01
AU1569599A (en) 1999-07-05
GB9726339D0 (en) 1998-02-11
JP2002508178A (ja) 2002-03-19
DE69839347D1 (de) 2008-05-21
WO1999031232A1 (en) 1999-06-24
EP1036175B1 (de) 2008-04-09
EP1036175A1 (de) 2000-09-20
US20060183105A1 (en) 2006-08-17
DE69839347T2 (de) 2009-05-07

Similar Documents

Publication Publication Date Title
ATE391779T1 (de) Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE3280344D1 (de) Verwendung von retinoiden und minoxidil (2,4-diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia.
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
HUP0100436A2 (hu) Emlős citokinszerű polipeptid-10
DE69622154T2 (de) Verwendung von angiogenese-suppressoren zur hemmung des haarwuchses
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
WO1997040017A3 (en) Modulators of molecules with phosphotyrosine recognition units
ATE254443T1 (de) Inhibitierung des haarwuchses
IL125711A0 (en) Human metabotropic glutamate receptor
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
MY131442A (en) Excitatory amino acid receptor antagonists
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69837267D1 (de) Kcnq kaliumkanäle und verfahren zur deren modulierung
DE69625877T2 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
ES2123582T3 (es) Proteina con capacidad de formacion de huesos y procedimiento para su produccion.
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
IT8567714A1 (it) Procedimento enzimatico di depilazione di pelli.
DE69621447T2 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
EA200001246A1 (ru) Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69940793D1 (de) Chimärisches Gen, dass für die antigenischen Determinanten von vier Proteinen aus L. Infantum kodiert
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen
DE59808165D1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties